Dedicated to bringing innovative solutions to the Ophthalmic community - providing benefits to Patients, Providers and Payers. Viewpoint Therapeutic’s lead candidate, a super-potent ophthalmic corticosteroid, indicated for inflammation and pain post-ocular surgery, was submitted to the FDA in May 2023. Expecting to launch in Q2, 2024 with patent exclusivity extending to 2036
Company Details
- Employees
- 1
- Founded
- -
- Address
- Sacramento, Ca, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- HQ
- Sacramento, CA
Viewpoint Therapeutics Questions
Viewpoint Therapeutics's LinkedIn profile is https://www.linkedin.com/company/vp-therapeutics
Viewpoint Therapeutics has
1 employees.
View email and phone details for 1
employees at Viewpoint Therapeutics.
Viewpoint Therapeutics's industry is
Pharmaceutical Manufacturing
Viewpoint Therapeutics's top competitors are
Convergent Genomics,
Cureline,
Imaginab,
Corvus Pharmaceuticals,
Interline Therapeutics,
Kezar Life Sciences,
Navidea Biopharmaceuticals,
Jlabs,
Yali Bio,
Acelot.
Viewpoint Therapeutics's categories are Pharmaceutical Manufacturing
Viewpoint Therapeutics's founding year is 2023
